NICE Pans Pomalidomide For Blood Cancer, Backs Xarelto In ACS Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. HTA rejects Celgene’s pomalidomide for treating multiple myeloma on cost grounds but waves through Bayer’s rivaroxaban for preventing blood clots in people who have had a heart attack.